GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (OTCPK:BIOYF) » Definitions » EV-to-EBIT

Biosyent (Biosyent) EV-to-EBIT : 8.46 (As of Apr. 27, 2024)


View and export this data going back to . Start your Free Trial

What is Biosyent EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biosyent's Enterprise Value is $54.04 Mil. Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $6.39 Mil. Therefore, Biosyent's EV-to-EBIT for today is 8.46.

The historical rank and industry rank for Biosyent's EV-to-EBIT or its related term are showing as below:

BIOYF' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.6   Med: 13.71   Max: 54.77
Current: 8.23

During the past 13 years, the highest EV-to-EBIT of Biosyent was 54.77. The lowest was 4.60. And the median was 13.71.

BIOYF's EV-to-EBIT is ranked better than
78.74% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.125 vs BIOYF: 8.23

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Biosyent's Enterprise Value for the quarter that ended in Dec. 2023 was $63.13 Mil. Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $6.39 Mil. Biosyent's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 10.11%.


Biosyent EV-to-EBIT Historical Data

The historical data trend for Biosyent's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent EV-to-EBIT Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.57 14.53 9.10 7.64 9.68

Biosyent Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.64 9.47 8.54 7.67 9.68

Competitive Comparison of Biosyent's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Biosyent's EV-to-EBIT falls into.



Biosyent EV-to-EBIT Calculation

Biosyent's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=54.040/6.385
=8.46

Biosyent's current Enterprise Value is $54.04 Mil.
Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (OTCPK:BIOYF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Biosyent's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=6.385/63.13136409
=10.11 %

Biosyent's Enterprise Value for the quarter that ended in Dec. 2023 was $63.13 Mil.
Biosyent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Biosyent's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent (Biosyent) Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.

Biosyent (Biosyent) Headlines

From GuruFocus

BioSyent to Present at The LD 500 Virtual Conference

By ACCESSWIRE ACCESSWIRE 08-25-2020

BioSyent Announces Approval of New Product

By GlobeNewswire GlobeNewswire 05-31-2023

BioSyent Schedules Q2 and H1 2022 Earnings Release for August 23, 2022

By GlobeNewswire GlobeNewswire 08-17-2022

BioSyent Announces Grant of Restricted Share Units

By GlobeNewswire GlobeNewswire 03-31-2023

BioSyent Announces Adoption of Restricted Share Unit Plan

By GlobeNewswire GlobeNewswire 03-06-2020

BioSyent to Present at Upcoming Investor Conferences

By GlobeNewswire GlobeNewswire 04-25-2018

BioSyent Announces Changes to Executive Management

By GlobeNewswire GlobeNewswire 09-10-2018

When Being Certain Isn't Enough

By Thomas Macpherson Thomas Macpherson 08-30-2019